Population Council

Knowledge Commons

2016

Increasing access to magnesium sulphate in Nigeria
Population Council

Follow this and additional works at: https://knowledgecommons.popcouncil.org/departments_sbsr-rh
Part of the Demography, Population, and Ecology Commons, Family, Life Course, and Society
Commons, International Public Health Commons, and the Maternal and Child Health Commons

How does access to this work benefit you? Let us know!
Recommended Citation
"Increasing access to magnesium sulphate in Nigeria," Ending Eclampsia Policy Brief. Washington, DC:
Population Council, 2016.

This Brief is brought to you for free and open access by the Population Council.

Policy brief

INCREASING ACCESS
TO MAGNESIUM
SULPHATE IN
NIGERIA
Maternal and newborn deaths due to
pre-eclampsia and eclampsia (PE/E) are
preventable, yet in Nigeria, this is the most
significant direct cause of maternal deaths.
THE PROBLEM
Despite global efforts to reduce preventable maternal and
neonatal mortality, Nigeria’s maternal mortality ratio is
estimated at 576 deaths per 100,000 live births and neonatal
death is estimated at 37 per 1,000 live births.
In Nigeria, hypertensive disorders in pregnancy (including
PE/E) is the most common cause of maternal mortality,
contributing to 29% of maternal deaths. As a major killer
of pregnant women, greater uptake of effective, low-cost
interventions to prevent, detect, and treat PE/E is needed at
primary health care facilities.
The World Health Organization (WHO) recommends
magnesium sulphate (MgSO4) as the most effective, safe, and
low-cost drug for treating pre-eclampsia and eclampsia.
To increase access and use of MgSO4 in Kano State, the
Population Council trained lower-cadre health care providers in
antenatal clinics to detect pre-eclampsia early and instituted
timely and appropriate management by administering the
loading dose of MgSO4 and referring for follow up care. This
intervention, supported by the John D. and Catherine T.
MacArthur Foundation, reduced the maternal mortality rate
due to PE/E by 40% in project sites.
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APPROACH
In preparation for the study, the Council engaged with
stakeholders and advocated for the adoption of protocols
allowing primarily health care providers to administer the
intramuscular (IM) loading dose of MgSO4 to women with
severe pre-eclampsia and eclampsia prior to referral to a
higher level facility. To gain acceptance of the proposed
intervention, the Council worked closely with representatives
from the Federal Ministry of Health and with community
gatekeepers, such as traditional leaders and social workers.

PE/E IN BRIEF
• Pre-eclampsia is a condition
in pregnant women marked by an
increase in blood pressure and
protein in urine after 20 weeks
gestation.
• Providing high quality antenatal care
improves the prevention and early
detection of pre-eclampsia and can
prevent its progression to eclampsia.
• Eclampsia is a life-threatening
condition characterized by
convulsions in women with PE.
• Women in developing countries are
300 times more likely to die from
eclampsia than women in developed
countries.
• Pre-eclampsia and eclampsia can
be managed by administering antihypertensive drugs and magnesium
sulphate (MgSO4).
• MgSO4 is the safest and most
effective treatment for severe preeclampsia and eclampsia, and is one
of the 13 UN Life-Saving Commodities
for Women and Children.
• PE/E and other hypertensive
disorders in pregnancy increase the
risk of pre-term births, which can
lead to low birth weight, anemia, and
stunting.
• Improved prevention, increased
detection, and effective treatment
of PE/E can prevent unnecessary
maternal and newborn deaths.
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Between 2008 and 2014, the intervention occurred
in two phases. The first phase (2008-2011) involved
selecting 10 secondary health facilities in Kano State.
Once selected, the Council then trained, mentored,
and supervised 40 providers from these facilities
to detect and manage PE/E patients. This included
training them to administer a loading dose of MgSO4.
Continued mentorship consisted of monthly visits
from trainers, and every patient with pre-eclampsia
or eclampsia was monitored for up to six weeks after
delivery.
The providers then trained and mentored additional
providers at their respective health facilities on the
use of MgSO4, which the Council supplied to the
facilities. Once the provided stock of MgSO4 ran out,
the state Ministry of Health took over procurement.
The second phase of the intervention (2012-2014)
focused on primary health care facilities, and divided
them into two groups – an experimental and a control.
In the experimental group, researchers trained
providers to administer a loading dose of MgSO4. In
the control group, researchers did not train providers
to use MgSO4.

RESULTS
Results showed that lower-cadre health providers can
reduce maternal mortality related to PE/E if trained

to administer MgSO4. Prior to the study, the Council
found maternal mortality caused by PE/E was at 15%
in Kano. In the experimental group, it decreased to
1.7%. In the control group, maternal deaths remained
the same.

SCALE UP
The Council intends to replicate this intervention in
other states in Nigeria to reduce maternal deaths
related to PE/E. Moving forward, the Council will
modify this intervention by also training providers at
primary health care facilities to manage hypertension
by using antihypertensive drugs and will include a
community component to increase awareness of signs
and symptoms and information that details where and
when to seek treatment.
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FIGURE 1 Kano Model for increaseing access to MgSO4
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